Other News To Note
Monday, January 28, 2013
Kineta Inc., of Seattle, said it secured exclusive, worldwide development rights from the University of Utah Research Foundation to a portfolio of drug candidates based on the Conotoxin Rg1a for the non-narcotic treatment of chronic pain.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.